Trial
NCT03627091
Efficacy and Safety Study of Ontamalimab as Maintenance Treatment in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 307)
Phase IIITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Shire
Collaborators
—
Condition
Crohn's Disease
Intervention
Ontamalimab
Why stopped
Sponsor decision to discontinue the SHP647 (ontamalimab) clinical trial development program for inflammatory bowel diseases (IBD) early.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-03-31